SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling…
$SLS OI after big put sweep in 9 puts jan 2027! https://t.co/4waLJJU8cK
Stocks with the highest short interest…do you own any of these?: $ONDS - Ondas - 41.56% $SOUN - SoundHound AI - 40.11% $RXRX - Recursion Pharmaceuticals - 33.39% $ASST - Strive - 31.65% $CLSK - CleanSpark - 30.60% $KSS - Kohl’s - 29.41% $SLS - SELLAS Life Sciences - 29.25%…
2 analysts rate SLS Strong Buy on consensus.
Consensus price target: $32.50 (+186.34% upside from $11.35)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kalin Katherine Bach director | Nov 19, 2025 | Purchase | 63,400 | $100.81K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-26.86M |
| 2024 | $0 | — | $-30.88M |
| 2023 | $0 | -100% | $-37.34M |
Stock data for SLS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics